Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Company Growth (employees)
Type
Public
HQ
New Haven, US
Founded
1992
Size (employees)
3,121 (est)
Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US

Alexion Pharmaceuticals Office Locations

Alexion Pharmaceuticals has offices in New Haven, Zürich, Barcelona, London and in 29 other locations
New Haven, US (HQ)
100 College St
Zürich, CH
30 Giesshübelstrasse

Alexion Pharmaceuticals Metrics

Alexion Pharmaceuticals Financial Metrics

Revenue (2016)

$3.1 b

Revenue growth (2015-16), %

18%

Gross profit

$2.8 b

Gross profit margin (2016), %

92%

Net income (2016)

$399 m

Market capitalization (28-Apr-2017)

$28.7 b

Closing share price (28-Apr-2017)

$126.9

Cash (31-Dec-2016)

$966 m
Alexion Pharmaceuticals's current market capitalization is $28.7 b.
Alexion Pharmaceuticals's revenue was reported to be $3.1 b in FY, 2016 which is a 18% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$1.6 b$2.2 b$2.6 b$3.1 b

Revenue growth, %

44%17%18%

Cost of goods sold

$233.1 m$258 m

Gross profit

$1.4 b$2.1 b$2.4 b$2.8 b

Gross profit Margin, %

89%92%91%92%

Operating expense total

$845.8 m$1.2 b$1.8 b$2.2 b

EBIT

$528 m$868.7 m$536.7 m$667 m

EBIT margin, %

34%39%21%22%

Interest expense

$47.7 m$97 m

Pre tax profit

$498.1 m$576 m

Income tax expense

$353.8 m$177 m

Net Income

$252.9 m$656.9 m$144.4 m$399 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$529.9 m$944 m$1 b$966 m

Accounts Receivable

Inventories

$102.6 m$176.4 m$289.9 m$375 m

Current Assets

$2.2 b$2.8 b$2.4 b$2.6 b

PP&E

$201.1 m$392.2 m$697 m$1 b

Goodwill

$254.1 m$254.1 m$5 b$5 b

Total Assets

$3.3 b$4.2 b$13.1 b$13.3 b

Accounts Payable

$21.6 m$44 m$57.4 m$64 m

Current Liabilities

$582.4 m$606.7 m$718.3 m$823 m

Additional Paid-in Capital

$2.1 b$2.6 b$7.7 b$8 b

Retained Earnings

$379.1 m$1 b$1.2 b$1.8 b

Total Equity

$2.4 b$3.3 b$8.3 b$8.7 b

Financial Leverage

1.4 x1.3 x1.6 x1.5 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$252.9 m$656.9 m$144.4 m$399 m

Depreciation and Amortization

$28.7 m$46.9 m$166.6 m$396 m

Accounts Receivable

($120 m)($28 m)($120 m)($120 m)

Inventories

$126 k($67 m)($88 m)($84 m)

Accounts Payable

Cash From Operating Activities

$497.3 m$640.1 m$675.2 m$1.1 b

Purchases of PP&E

($29.3 m)($136.7 m)($286.3 m)($333 m)

Cash From Investing Activities

($1 b)($222.9 m)($3.6 b)($287 m)

Cash From Financing Activities

$71.6 m$7.1 m$3 b($836 m)

Interest Paid

$2.8 m$1.9 m$41.4 m$80 m

Income Taxes Paid

$76.2 m$91.2 m$123.2 m$38 m

Alexion Pharmaceuticals Market Value History

Alexion Pharmaceuticals Median Salaries

Source: 33 public H-1B filings from Alexion Pharmaceuticals

Alexion Pharmaceuticals Online Presence

Alexion Pharmaceuticals News

Alexion Pharmaceuticals Company Life

You may also be interested in